Results 201 to 210 of about 20,292 (247)

Targets Beyond LDL in ASCVD Prevention

Indian Journal of Clinical Cardiology
openaire   +1 more source

Risk of ASCVD and Non-ASCVD Hospitalizations for Triglycerides Across CKD Stages Among 2 Million US Veterans

, 2019
Soohoo, Melissa, Hsiung, Jui-Ting, Park, Christina, Marroquin, Maria, Moradi, Hamid, Kovesdy, Csaba, Kalantar-Zadeh, Kamyar, Streja, Elani   +7 more
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

HDL and ASCVD

Advances in Experimental Medicine and Biology, 2022
In this chapter, we summarize the relationship between circulating high-density lipoprotein (HDL) and atherosclerotic cardiovascular disease (ASCVD). HDL acts in many types of cells, such as endothelial cell, macrophage, T lymphocyte, etc. Recently, novel HDL-related therapies have been developed to treat ASCVD.
Hongtu, Cui, Qian, Du
exaly   +3 more sources

Lipid profile screening and ASCVD prevention

Expert Review of Cardiovascular Therapy, 2023
Atherosclerotic cardiovascular disease (ASCVD) is the main cause of morbidity and mortality worldwide. Dyslipidemia, in particular elevation of LDL-cholesterol levels (LDL-C), is one of the major cardiovascular risk factors and is characterized by high prevalence and independent unfavorable impact on cardiovascular prognosis; however, because of its ...
Massimo R Mannarino, Matteo Pirro
exaly   +3 more sources

Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions

Current Atherosclerosis Reports, 2020
Purpose of review: This review focuses on recent evidence examining the role triglycerides (TG) and triglyceride-enriched lipoproteins (TGRL) play in atherosclerotic cardiovascular disease (ASCVD).
Aliza Hussain, Christie M Ballantyne, Anum Saeed   +2 more
exaly   +2 more sources

Mediation effect of platelet indices on the association of daytime nap duration with 10-year ASCVD risk

Platelets, 2021
Daytime nap is associated with the risk of atherosclerotic cardiovascular disease (ASCVD). However, the contribution of platelet to the association of daytime nap with ASCVD remains unclear.
Jian Hou, Yun Zhou, Chongjian Wang
exaly   +2 more sources

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score [PDF]

Frontiers in Cardiovascular Medicine, 2023
BackgroundThe intermediate metabolites associated with the development of atherosclerotic cardiovascular disease (ASCVD) remain largely unknown. Thus, we conducted a large panel of metabolomics profiling to identify the new candidate metabolites that ...
Shaghayegh Hosseinkhani, Niloufar Najjar, Dehghanbanadaki Hojat   +2 more
exaly   +2 more sources

Health Disparities Across the Continuum of ASCVD Risk

Current Cardiology Reports, 2022
Despite marked progress in cardiovascular disease management in the last several decades, there remain significant, persistent disparities in cardiovascular health in historically marginalized racial and ethnic groups. Here, we outline current state of health disparities in cardiovascular disease, discuss the interplay between social determinants of ...
Ankita Devareddy, Ashish Sarraju, Fatima Rodriguez   +2 more
openaire   +2 more sources

Comparative efficacy of anthropometric indices in predicting 10-year ASCVD risk: insights from NHANES data [PDF]

Frontiers in Cardiovascular Medicine
BackgroundCardiovascular diseases remain a leading cause of morbidity and mortality worldwide. Accurately predicting the 10-year risk of Atherosclerotic Cardiovascular Disease (ASCVD) is crucial for timely intervention and management. This study aimed to
Zeng Ling
exaly   +2 more sources